Heparin-induced thrombocytopenia (HIT) is a clinically significant immune-mediated adverse reaction to heparin therapy. It is typified by a reduction in circulating platelets while paradoxically ...
A team of researchers developed 3 quality improvement measures embedded in electronic health records (EHRs) to improve care delivery in patients with heparin-induced thrombocytopenia. HIT is known as ...
In December 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics. VLX-1005 is a first-in-class, ...
Due to the potential for life- and limb-threatening complications, effective and immediate management of HIT is vital. When HIT is suspected, it is imperative to remove all forms of heparin, including ...
Purpose: A case of heparin-induced thrombocytopenia (HIT) complicated by warfarin-induced skin necrosis (WISN) is reported. Summary: A patient with a history of hypertension, heart failure, and ...
Heparin-induced thrombocytopenia (HIT) is an immune-mediated platelet disorder caused by antibodies that target complexes of platelet factor 4 (PF4) and heparin. HIT has been characterized as a ...
Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase 2 ...
PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of ...
Global Heparin Market OverviewThe Global Heparin Market is projected to grow steadily at a CAGR of approximately 5% by 2026.
Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results